Premium
Tofisopam and midazolam: differences in clinical effects and in changes of CSF monoamine metabolites.
Author(s) -
HoviViander M.,
Kanto J.,
Scheinin H.,
Scheinin M.
Publication year - 1985
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1985.tb05105.x
Subject(s) - monoamine neurotransmitter , placebo , midazolam , homovanillic acid , anesthesia , benzodiazepine , medicine , sedative , dopaminergic , pharmacology , dopamine , sedation , serotonin , alternative medicine , receptor , pathology
The effect of two repeated oral doses of 100 mg tofisopam 15 mg midazolam and placebo on the concentrations of monoamine metabolites (MHPG, 5‐HIAA, HVA) in lumbar CSF were studied in general surgical patients operated on under spinal analgesia (n = 12 in each group). Midazolam, but not tofisopam, improved the quality of sleep the night before surgery. Both active agents reduced preoperative anxiety of the patients, but tofisopam was without subjective sedative action. In the placebo group, in contrast to the active drug groups, there was a slight positive correlation between the MHPG concentration and degree of anxiety before surgery. The only significant difference in the monoamine metabolites in lumbar CSF was found in the concentrations of HVA between tofisopam and placebo treated patients. The lower HVA concentrations suggest that the curious 3,4‐benzodiazepine derivative, tofisopam, modifies central dopaminergic activity.